SynthesisImmunity, inflammation and disease2026
Risk Factors of Disease Progression in IgA Nephropathy: A Systematic Review and Meta-Analysis.
Synthesis in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effectiveness and Safety of Nefecon in Primary IgA Nephropathy Across Different Baseline Proteinuria Levels: A Real-World Study.Advances in therapy · 2026Article
- Development and validation of a routine urinalysis-based risk stratification model for IgA nephropathy in a multicenter real-world hospital population.Frontiers in nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIgA nephropathy (IgAN) is an important cause of chronic renal failure, and nearly all patients with IgAN are at risk of developing to end-stage renal disease (ESRD) during their lifetime. This meta-analysis aimed to identify and evaluate risk factors associated with the progression of IgAN patients.
methodsPrimary studies investigating the risk factors for predicting the progression of IgAN were included in this review. A comprehensive literature search was conducted across multiple electronic databases, including the Chinese Biological Medicine Database (CBM), China National Knowledge Infrastructure (CNKI), Cochrane Library, PubMed, Embase, Web of Science, and WANFANG, up to May 30, 2025. Two independent reviewers screened the literature based on the predefined inclusion and exclusion criteria, extracted the relevant data from the original studies, and assessed the quality of the included studies using the Newcastle-Ottawa Scale (NOS). Meta-analysis was performed on at least two studies reporting on a specific outcome, with pooled effect sizes expressed as hazard ratios (HRs) and 95% confidence intervals (CIs). Statistical analysis, including meta-analysis, subgroup analysis and sensitivity analysis, was conducted using the R software. Publication bias was evaluated using Egger's test in Stata12.0.
resultsA total of 53 studies, comprising 25,517 patients with IgAN, were included in the final analysis. This meta-analysis identified 10 clinical risk factors significantly associated with IgAN progression, including mean arterial pressure (MAP) (HR = 1.02, 95% CI: 1.01-1.03), diastolic blood pressure (DBP) (HR = 1.03, 95% CI: 1.01-1.05), systolic blood pressure (SBP) (HR = 1.03, 95% CI: 1.01-1.05), serum creatinine (SCr) (HR = 1.04, 95% CI: 1.03-1.06), triglyceride (HR = 1.11, 95% CI: 1.02-1.21), 24-h urinary protein excretion (UPE) (HR = 1.15, 95% CI: 1.12-1.18), low-density lipoprotein cholesterol (LDL-C) (HR = 1.37, 95% CI: 1.18-1.59), male sex (vs. female) (HR = 1.73, 95% CI: 1.16-2.59), complement C4 (C4) (HR = 1.81, 95% CI: 1.06-3.09), and hypertension (HR = 2.53, 95% CI: 1.92-3.33). The pathological features significantly predictive of IgAN progression including crescents (C1/C2) (vs. C0) (HR = 1.57, 95% CI: 1.24-1.99), C2 (vs. C0) (HR = 2.87, 95% CI: 1.65-5.01), endocapillary hypercellularity (E1) (vs. E0) (HR = 1.17, 95% CI: 1.02-1.35), segmental glomerulosclerosis (S1) (vs. S0) (HR = 2.23, 95% CI: 1.78-2.79), and tubular atrophy (T1/T2) (vs. T0) (HR = 5.12, 95% CI: 3.56-7.36), when analyzed individually, T1 (vs. T0) showed an HR = 4.59 (95% CI: 3.24-6.51), and T2 (vs. T0) showed an HR = 16.40 (95% CI: 9.65-27.87). In contrast, C1 (vs. C0) (HR = 1.41, 95% CI: 0.81-2.45) was not significantly associated with progression risk. Protective factors against lgAN progression included higher level of albumin (Alb) (HR = 0.95, 95% CI: 0.93-0.98), estimated glomerular filtration rate (eGFR) (HR = 0.96, 95% CI: 0.95-0.97), hemoglobin (Hb) (HR = 0.98, 95% CI: 0.97-0.99), complement C3 (C3) (HR = 0.97, 95% CI: 0.95-0.99). Additionally, female sex was associated with a lower risk of disease progression, with HR = 0.69 (95% CI: 0.57-0.84) and when compared directly with male HR = 0.55 (95% CI: 0.45-0.67).
conclusionThis meta-analysis indicates that MAP, DBP, SBP, SCr, triglyceride, 24-h UPE, LDL-C, male sex (vs. female), C4, hypertension, C-lesions, M-lesions, S-lesions, and T-lesions in Oxford classification are significantly associated with an increased risk of IgAN progression. In contrast, higher levels of Alb, eGFR, Hb, C3, as well as female sex (both as an independent variable and compared with males), are identified as protective factors in patients with IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.